IL272361B2 - Antibody binding active alpha-synuclein - Google Patents

Antibody binding active alpha-synuclein

Info

Publication number
IL272361B2
IL272361B2 IL272361A IL27236120A IL272361B2 IL 272361 B2 IL272361 B2 IL 272361B2 IL 272361 A IL272361 A IL 272361A IL 27236120 A IL27236120 A IL 27236120A IL 272361 B2 IL272361 B2 IL 272361B2
Authority
IL
Israel
Prior art keywords
synuclein
active
antibody
monoclonal antibody
disease
Prior art date
Application number
IL272361A
Other languages
English (en)
Hebrew (he)
Other versions
IL272361B1 (en
IL272361A (en
Original Assignee
Stressmarq Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressmarq Biosciences Inc filed Critical Stressmarq Biosciences Inc
Publication of IL272361A publication Critical patent/IL272361A/en
Publication of IL272361B1 publication Critical patent/IL272361B1/en
Publication of IL272361B2 publication Critical patent/IL272361B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL272361A 2017-08-02 2018-08-02 Antibody binding active alpha-synuclein IL272361B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762540435P 2017-08-02 2017-08-02
PCT/CA2018/050952 WO2019023809A1 (en) 2017-08-02 2018-08-02 ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEINE

Publications (3)

Publication Number Publication Date
IL272361A IL272361A (en) 2020-03-31
IL272361B1 IL272361B1 (en) 2025-02-01
IL272361B2 true IL272361B2 (en) 2025-06-01

Family

ID=65232133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272361A IL272361B2 (en) 2017-08-02 2018-08-02 Antibody binding active alpha-synuclein

Country Status (10)

Country Link
US (2) US11098108B2 (cg-RX-API-DMAC7.html)
EP (1) EP3661961A4 (cg-RX-API-DMAC7.html)
JP (1) JP7204235B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826089B1 (cg-RX-API-DMAC7.html)
CN (1) CN111225923B (cg-RX-API-DMAC7.html)
AU (1) AU2018312441B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020001970A2 (cg-RX-API-DMAC7.html)
IL (1) IL272361B2 (cg-RX-API-DMAC7.html)
SA (1) SA520411188B1 (cg-RX-API-DMAC7.html)
WO (1) WO2019023809A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US12049493B2 (en) 2017-01-06 2024-07-30 Abl Bio Inc. Anti-alpha-synuclein antibodies and uses thereof
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
IL270361B2 (en) 2017-05-01 2025-04-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
BR112020011875A2 (pt) 2017-12-14 2020-11-24 Abl Bio Inc. anticorpo biespecífico ao a-syn/igf1r e uso do mesmo
EP3985022A4 (en) * 2019-06-14 2023-08-02 ABL Bio, Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE
IL293108A (en) * 2019-11-19 2022-07-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein, and methods of using them
NL2025332B1 (en) 2020-04-10 2021-10-26 Syngle Therapeutics B V Novel alpha-synuclein binding antibodies, or antigen binding portions thereof.
KR102505164B1 (ko) * 2020-09-29 2023-02-28 서울대학교산학협력단 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물
CN113912713B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 一种抗α-突触核蛋白的单克隆抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3823313A1 (de) 1988-07-09 1990-01-11 Henkel Kgaa Fussbodenreinigungsgeraet
US20040143093A1 (en) 2002-07-11 2004-07-22 Ralph Zahn Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2709048T3 (es) 2008-04-29 2019-04-15 Bioarctic Ab Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN110655573B (zh) * 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN103443125B (zh) 2010-11-30 2019-05-03 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2807188B1 (en) * 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
EA035517B1 (ru) 2014-03-06 2020-06-29 Нэшнл Рисеч Каунсил Оф Канада Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
EP3114142B1 (en) 2014-03-06 2019-06-05 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子1受容体特異的抗体及びそれらの使用
CN103983778B (zh) * 2014-05-08 2016-04-13 首都医科大学宣武医院 一种检测受实验者体液体外促进疾病相关蛋白聚合能力的方法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COVELL, D. J., ET AL., NOVEL CONFORMATION?SELECTIVE ALPHA?SYNUCLEIN ANTIBODIES RAISED AGAINST DIFFERENT IN VITRO FIBRIL FORMS SHOW DISTINCT PATTERNS OF LEWY PATHOLOGY IN PARKINSON'S DISEASE., 15 May 2017 (2017-05-15) *
EL-AGNAF, OMAR, ET AL., DIFFERENTIAL EFFECTS OF IMMUNOTHERAPY WITH ANTIBODIES TARGETING ALPHA-SYNUCLEIN OLIGOMERS AND FIBRILS IN A TRANSGENIC MODEL OF SYNUCLEINOPATHY., 2 May 2017 (2017-05-02) *
FAGERQVIST, THERESE, ET AL., MONOCLONAL ANTIBODIES SELECTIVE FOR ALPHA-SYNUCLEIN OLIGOMERS/PROTOFIBRILS RECOGNIZE BRAIN PATHOLOGY IN LEWY BODY DISORDERS AND ALPHA-SYNUCLEIN TRANSGENIC MICE WITH THE DISEASE-CAUSING A30P MUTATION., 27 February 2013 (2013-02-27) *
VAIKATH, NISHANT N., ET AL., GENERATION AND CHARACTERIZATION OF NOVEL CONFORMATION-SPECIFIC MONOCLONAL ANTIBODIES FOR ALPHA-SYNUCLEIN PATHOLOGY., 30 April 2015 (2015-04-30) *

Also Published As

Publication number Publication date
WO2019023809A1 (en) 2019-02-07
US11098108B2 (en) 2021-08-24
JP7204235B2 (ja) 2023-01-16
EP3661961A4 (en) 2021-04-14
CN111225923B (zh) 2024-09-24
CA3071634A1 (en) 2019-02-07
US20210139569A1 (en) 2021-05-13
BR112020001970A2 (pt) 2020-08-04
US11919947B2 (en) 2024-03-05
EP3661961A1 (en) 2020-06-10
KR102826089B1 (ko) 2025-06-30
IL272361B1 (en) 2025-02-01
IL272361A (en) 2020-03-31
US20210355202A1 (en) 2021-11-18
CN111225923A (zh) 2020-06-02
SA520411188B1 (ar) 2023-01-08
AU2018312441A1 (en) 2020-02-06
AU2018312441B2 (en) 2024-10-17
KR20200033880A (ko) 2020-03-30
JP2020529473A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
US11919947B2 (en) Antibody binding active α-synuclein
US20250250331A1 (en) Anti-age antibodies for treating neurodegenerative disorders
DK2282758T3 (en) ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS
IL261006A (en) Method and preparation for the treatment of cancer, killing of metastatic cancer cells and prevention of cancer metastases using an antibody to advanced glycation end products
US10889634B2 (en) Anti-age antibodies and methods of use thereof
AU2016336959A1 (en) Anti-age antibodies and methods of use thereof
JP2022541539A (ja) 抗タウ抗体およびその使用
IL251210B1 (en) Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
Hettmann et al. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation
IL300059A (en) Anti-Abata antibodies
WO2016053610A1 (en) Antibodies against pathological forms of tdp-43 and uses thereof
Silverman et al. A rational structured epitope defines a distinct subclass of toxic amyloid-beta oligomers
Kreutzer et al. Antibodies raised against an Aβ oligomer mimic recognize pathological features in Alzheimer’s disease and associated amyloid-disease brain tissue
WO2022060236A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
US9796778B1 (en) Antibodies against pathological forms of TDP-43 and uses thereof
CA3071634C (en) Antibody binding active alpha-synuclein
IL321347A (en) Fusion comprising anti-tau antibody and peptide and use thereof
IL296573A (en) Antibodies against areg and their uses
HK40022840B (en) ANTIBODIES TO α‐SYNUCLEIN AND USES THEREOF